

Australian Government

Department of Health

Therapeutic Goods Administration

Public Summary

Summary for ARTG Entry: 316340 Orthoplex Glutamine Complex 500

ARTG entry for Medicine Listed

Sponsor Bio Concepts Pty Ltd

Postal Address PO Box 190, Banyo, Brisbane, QLD, 4014

Australia

ARTG Start Date 10/04/2019
Product Category Medicine
Status Active

Approval Area Listed Medicines

Conditions

Colouring agents used in listed medicine for ingestion, other than those listed for export only under section 25 of the Act, shall be only those included in the list of 'Colourings permitted in medicines for oral use'.

The sponsor shall keep records relating to this listed medicine as are necessary to: (a) Expedite recall if necessary of any batch of the listed medicine, (b) Identify the manufacturer(s) of each batch of the listed medicine. Where any part of or step in manufacture in Australia of the listed medicine is sub-contracted to a third party who is not the sponsor, copies of relevant Good Manufacturing Practice agreements relation to such manufacture shall be kept.

The sponsor shall retain records of the distribution of the listed medicine for a period of five years and shall provide the records or copies of the records to the Complementary Medicines Branch, Therapeutic Goods Administration, upon request.

The sponsor of the listed medicine must not, by any means, intentionally or recklessly advertise the medicine for an indication other than those accepted in relation to the inclusion of the medicine in the Register.

All reports of adverse reactions or similar experiences associated with the use or administration of the listed medicine shall be notified to the Head, Office of Product Review, Therapeutic Goods Administration, as soon as practicable after the sponsor of the goods becomes aware of those reports. Sponsors of listed medicines must retain records of such reports for a period of not less than 18 months from the day the Head, Office of Product Review is notified of the report or reports.

The sponsor shall not supply the listed medicine after the expiry date of the goods.

Where a listed medicine is distributed overseas as well as in Australia, product recall or any other regulatory action taken in relation to the medicine outside Australia which has or may have relevance to the quality, safety or efficacy of the goods distributed in Australia, must be notified to the National Manager Therapeutic Goods Administration, immediately the action or information is known to the sponsor.

Products

1 . Orthoplex Glutamine Complex 500

Product Type Single Medicine Product Effective Date 10/04/2019

Permitted Indications

Helps maintain/support healthy acid/alkali balance in the body

Maintain/support general health and wellbeing

Aid/assist healthy red blood cell production

Maintain/support red blood cell health

Helps maintain/support healthy blood sugar/glucose

Maintain/support blood health

Helps maintain/support haemoglobin formation/synthesis

Maintain/support cardiovascular system health

Maintain/support healthy cardiovascular system function

Maintain/support healthy mucous linings of the digestive system

Maintain/support gastrointestinal system health

Maintain/support healthy gastrointestinal function

Maintain/support gastrointestinal mucosal membrane health

Aids/assists repair of gastrointestinal/gut wall lining

Maintain/support immune system health

Maintain/support healthy immune system function

Maintain/support healthy gastrointestinal immune function

Aid/assist/helps glucose/sugar/carbohydrate metabolism

Helps decrease/reduce homocysteine levels

Page 1 of 3



Australian Government

Department of Health

Therapeutic Goods Administration

Aid/assist/helps protein synthesis in the body

Maintain/support (state vitamin/mineral/nutrient) levels in the body

Helps maintain/support cellular uptake of (state vitamin/mineral/nutrient)

Helps prevent dietary (state vitamin/mineral/nutrient) deficiency

Aid/assist/helps metabolism of (state vitamin/mineral/nutrient)

Aid/assist/helps synthesis of neurotransmitters

Maintain/support nervous system health

Maintain/support nervous system function

Indication Requirements

Product presentation must not imply or refer to mental illnesses, disorders or conditions.

Product presentation must not imply or refer to serious cardiovascular conditions.

Product presentation must not imply or refer to lowering or raising blood sugar/glucose levels from outside of the normal healthy range.

Label statement: Vitamins and minerals can only be of assistance if dietary intake is inadequate OR Vitamin and/or mineral supplements should not replace a balanced diet.

Product presentation must not imply or refer to serious immunological diseases.

If product is indicated for supplementation, Label statement: Vitamins and minerals can only be of assistance if dietary intake is inadequate OR Vitamin and/or mineral supplements should not replace a balanced diet.

Label statement: If symptoms persist, talk to your health professional.

Standard Indications

No Standard Indications included on Record

Specific Indications

No Specific Indications included on Record

Warnings

If symptoms persist consult your healthcare practitioner (or words to that effect).

Vitamins can only be of assistance if the dietary vitamin intake is inadequate. OR Vitamin supplements should not replace a balanced diet.

Additional Product information

Pack Size/Poison information

Pack Size Poison Schedule

Components

1 . Formulation 1

Dosage Form Tablet, film coated

Route of Administration Oral

Visual Identification

Active Ingredients

| chromic chloride hexahydrate | 99.95 microgram |
|------------------------------|-----------------|
| Equivalent: chromium | 19.5 microgram |
| glutamine | 500 mg |
| magnesium amino acid chelate | 100 mg |
| Equivalent: magnesium | 20 mg |
| pyridoxine hydrochloride | 4.02 mg |
| Equivalent: pyridoxine | 3.3 mg |
| zinc amino acid chelate | 10 mg |
| Equivalent: zinc | 2 mg |

Other Ingredients (Excipients)

calcium hydrogen phosphate dihydrate

Carnauba Wax

hypromellose

macrogol 400

magnesium stearate

Page 2 of 3

Produced at 24.11.2020 at 08:46:54 AEDT



Department of Health

Therapeutic Goods Administration

microcrystalline cellulose povidone powdered cellulose silicon dioxide

© Commonwealth of Australia. This work is copyright. You are not permitted to re-transmit, distribute or commercialise the material without obtaining prior written approval from the Commonwealth. Further details can be found at http://www.tga.gov.au/about/website-copyright.htm.